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Abstract
The presence of a tumour is very often associated with wasting in the host, affecting
both skeletal muscle and adipose tissue. In the present study we used sorafenib, a
multi-kinase inhibitor with anti-tumour activity, in order to investigate the effects of
chemotherapy on wasting. Three different experimental mouse tumour models
were included: C26 colon carcinoma, B16 melanoma and Lewis lung carcinoma
(LLC). The results obtained clearly show that sorafenib was effective in reducing
tumour growth in LLC and B16 models, while it had no effect on C26. Interestingly,
sorafenib treatment reduced the signs of muscle wasting and improved the physical
activity in the LLC model and also in the C26, despite the absence of antineoplastic
action in the latter. Our results discard a role for IL-6 in the action of sorafenib since
the drug did not affect the levels of this cytokine. Conversely, sorafenib seems to
act by influencing both STAT3 and ERK activity at muscle level, leading to reduced
accumulation of Pax7 and atrogin-1. Sorafenib may interfere with muscle wasting
by decreasing the activation of these signal transduction pathways.
Introduction
Development of cachexia is often found in cancer patients. It occurs in 50 to 80%
of these patients [1], and is considered as a predictor of reduced survival
accounting for more than 20% of cancer patients deaths [2]. It reduces physical
activity [3] and quality of life and diminishes the tolerance to anticancer therapy
[4, 5]. Cachexia is defined, according to an international consensus [6], as a
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‘‘complex metabolic syndrome associated with underlying illness and character-
ized by loss of muscle with or without loss of fat mass. The prominent clinical
feature of cachexia is weight loss in adults (corrected for fluid retention) or
growth failure in children (excluding endocrine disorders). Anorexia, inflamma-
tion, insulin resistance and increased muscle protein breakdown are frequently
associated with cachexia. Cachexia is distinct from starvation, age-related loss of
muscle mass, primary depression, malabsorption and hyperthyroidism and is
associated with increased morbidity’’. The metabolic disturbances found in the
cancer patient include an increased energy inefficiency, insulin resistance and
altered carbohydrate metabolism, adipose tissue dissolution and hypertriglycer-
idemia and muscle wasting. All of these alterations have a causative role in the
development of the cachexia syndrome [7, 8].
The loss of body weight results from both decreased adipose tissue and muscle;
however, muscle wasting should be regarded as the most important since it plays a
key role in recovery from cancer cachexia. Thus, it is an important determinant of
survival and muscle strength and function, central to the recovery process [9].
Muscle wasting occurs when synthesis is decreased, breakdown is increased, or a
combination of events leads to a net negative balance. The regulation of skeletal
muscle is managed by several transcription factors and intracellular signalling
pathways (anabolic or catabolic), and a chronic imbalance in the activation of
these different pathways leads to muscle wasting [10–12]. Although there are
several mediators involved in the metabolic alterations linked to muscle wasting,
pro-inflammatory cytokines seem to play a major role [13].
Many efforts have been involved in designing a treatment for the cachectic
syndrome, but unfortunately there is not a single one fully satisfactory in reversing
weight loss. The development of different therapeutic strategies has focused on
two targets: counteracting anorexia and neutralizing metabolic disturbances [14].
However, providing complete nutritional requirements by way of total parenteral
nutrition does not abrogate weight loss [8]. Instead, many drugs have been
proposed and used in clinical trials [15, 16], while others are still under
investigation using experimental animals in order to revert metabolic alterations
[17, 18]. However, there are no effective treatments actually adopted in the clinical
practice.
During the last decades several experimental models were established to study
cancer cachexia [19]. However, tumour-injected animals as substitute for cancer
patients have a major drawback in the omission of anti-tumour treatments that
frequently complicate patient management. Such treatments might improve, do
not affect, or even worsen cachexia, according to their effectiveness in getting rid
of the tumour or to secondary adverse effects.
New focused cancer treatments are less toxic than traditional chemotherapy.
Such therapies ought to make tumour cells more susceptible, without increasing
host toxicity. From this point of view, sorafenib is a multikinase inhibitor that has
shown efficacy against a wide variety of tumours in preclinical models [20] and it
has been approved in humans for the treatment of advanced hepatocellular
carcinoma [21] and advanced renal cell carcinoma[22]. Nevertheless, Antoun
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et al. [23] reported that long term administration of sorafenib is associated with
muscle wasting in patients with advanced renal cell carcinoma. Recent studies
showed that it inhibits cell proliferation by targeting the Raf/MEK/ERK signalling
pathways and exerts an anti-angiogenic effect by inhibition of tumour
angiogenesis through VEGFR and PDGFR [24, 25]. Recently Yang et al. [26]
reported that sorafenib treatment blocked the IL-6-dependent STAT3 phos-
phorylation in cancer cells. Such effect is mediated by the inhibition of STAT3 up-
stream kinases JAK1 and JAK2 [27]. IL-6 is a critical cytokine secreted in several
cancer types, and circulating levels of this cytokine have been shown to correlate
with weight loss in cancer patients and reduced survival [28, 29].
The aim of the present study was to characterize the cachectic phenotype of
three commonly used experimental tumours in mice treated with sorafenib, in
order to provide a reliable tool for translational research.
Materials and Methods
Experimental tumour models
C57BL/6 (for LLC and B16 tumour models) or Balb/C (for C26 tumour model)
mice weighing about 20 g (Harlan, Barcelona, Spain) were maintained on a
regular dark-light cycle (light from 08:00 to 20:00), with free access to food and
water during the whole experimental period. They were cared for in compliance
with the Policy on Humane Care and Use of Laboratory Animals (ILAR 2011). The
Bioethical Committee of the University of Barcelona approved the experimental
protocol. All animal manipulations were made in accordance with the European
Community guidelines for the use of laboratory animals.
The mice were randomized and divided into two groups, namely controls (C,
n56) and tumour bearers (TB). TB mice were inoculated alternatively
subcutaneously in the back with 56105 B16 or C26 cells or i.m. (hind leg) with
56105 LLC cells (see below for cell expansion). TB animals were divided into two
sub-groups: untreated (n58) and treated (intragastric administration) every day
with sorafenib (90 mg/kg of initial body weight; n58). Mice were sacrificed under
anaesthesia 14 days after tumour implantation. The day of sacrifice, the animals
were weighed and anaesthetized with an intraperitoneal injection of ketamine/
xylazine mixture (3:1; ImalgeneH and RompunH respectively). Several tissues and
the tumour were rapidly excised, weighed, and frozen in liquid nitrogen.
Colon26 carcinoma (C26) and B16 melanoma (B16) cells were maintained in
vitro in Dulbecco’s Modified Eagle’s Medium (DMEM, Invitrogen) supplemented
with 10% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin, 100 mg/mL sodium
pyruvate, 2 mM L-glutamine, at 37 C˚ in a humidified atmosphere of 5% CO2 in
air. The day of tumour implantation the cells were trypsinized, re-suspended in
sterile saline and rapidly injected in the mice. Lewis lung carcinoma (LLC) cells
were obtained from previous tumour hosts harvesting the cells in the exponential
growth phase. The LLC is a cachexia-inducing, rapidly growing murine metastatic
tumour composed by poorly differentiated cells, with a relatively short doubling
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time. The number of lung metastases was evaluated by light microscopy after
necropsy. The metastases weight was evaluated according the methodology used
by Donati et al [30].
Haematocrit
Total blood was withdrawn from anaesthetized mice by cardiac puncture and
collected in heparinized tubes. A drop was used to fill haematocrit capillary tubes
that were centrifuged in a haematocrit centrifuge for 5 min at 800 x g.
Haematocrit was calculated as percentage of packed cell volume of the total blood.
Total physical activity
Total physical activity (IR ACTIMETER System and ACTITRAK software from
Panlab, Barcelona) was determined during the last 24 hours before the sacrifice of
the animals in control mice and tumour-bearing mice (both non-treated and
treated with sorafenib), using activity sensors which translate individual changes
in the infrared pattern caused by movements of the animals into arbitrary activity
counts. For the measurements, animals remained in their home cage. A frame
containing an infrared beam system was placed on the outside of the cage; this
minimised the stress of the animals.
ELISA
IL-6 serum levels were detected by a commercially available mouse ELISA kit,
used according to the manufacturer instructions (Diaclone, bioNova, Spain).
Serum from each animal (50 mL) was assayed in duplicate. Quantitative
calibration was obtained performing a standard curve with recombinant mouse
IL-6.
Western Blotting
50 mg of gastrocnemius muscle were homogenized in 10 mM HEPES, pH 7.5,
containing 10 mM MgCl2, 5 mM KCl, 0.1 mM EDTA, pH 8.0, 0.1% Triton X-
100, with freshly added protease and phosphatase inhibitors. Samples were then
centrifuged (5 min, 3000 g), the supernatant collected as the cytosolic fraction
and the pellet resuspended in 20 mM HEPES, pH 7.9, containing 25% glycerol,
500 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, pH 8.0, protease and phosphatase
inhibitor and incubated on ice for 30 min. Cell debris were removed by
centrifugation (5 min, 3000 g) and the supernatant (nuclear fraction) collected.
Protein concentration was assayed using BSA as working standard. Equal amounts
of protein (30 mg) were heat-denaturised in sample-loading buffer (50 mM Tris-
HCl, pH 6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol blue, 10% glycerol),
resolved by SDS-PAGE and transferred to nitrocellulose membranes. The filters
were blocked with Tris-buffered saline (TBS) containing 0.05% Tween and 5%
non-fat dry milk and then incubated overnight with antibodies directed against:
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p-ERK (Tyr204), total-ERK, total-STAT3 and GAPDH (Santa Cruz
Biotechnology, USA), FoxO3a and p-STAT3 (Tyr705; Cell Signalling Technology,
Danvers, MA, USA), Atrogin-1 (ECM Biosciences, Versailles, KY) and the
monoclonal antibody against Pax7 developed by Atsushi Kawakami, obtained
from the Developmental Studies Hybridoma Bank (University of Iowa).
Peroxidase-conjugated IgG (Bio-Rad, Hercules, USA) was used as secondary
antibody. Membrane-bound immune complexes were detected by an enhanced
chemiluminescence system (Santa Cruz Biotechnology, USA) on a photon-
sensitive film (Hyperfilm ECL, GE Healthcare). Protein loading was normalized
according to GAPDH expression. Quantification of the bands was performed by
densitometric analysis using the ImageJ software.
Statistical analysis
Statistical analysis of the data was performed by means of one-way analysis of
variance (ANOVA). Statistically significant differences was analysed by post hoc
Duncan test. All statistical tests were performed using SPSS version 21.
Results and Discussion
In order to ascertain the effects of sorafenib on tumour-bearing animals we used
three distinct experimental models: C26 colon carcinoma, B16 melanoma and
Lewis lung carcinoma (LLC). All of them are associated with a clear cachectic
response. From this point of view, as can be seen in Figure 1, body weight was
reduced in all models as a consequence of tumour burden (23% C26, 12% B16,
24% LLC). Similar to the human condition, the reduction of body weight was
associated with hypophagia in all the experimental models (Figure 1).
Treatment with the anti-tumour sorafenib-inhibitor of the MAPK cascade-
resulted in a huge reduction in tumour mass in the B16-bearing mice (94%) while
it exerted only a small effect in the LLC (20% reduction of primary tumour mass
and 98% fall of metastases number) (Figure 2). Remarkably, sorafenib had no
effect on C26 tumour growth (Figure 2). The anti-tumoural treatment was able to
markedly recover body weight in B16-bearing animals and also resulted in
significant increases in body weight in C26 and LLC models although at a lesser
extent than in the B16 model (Figure 1).
In the B16 model, sorafenib treatment increased food intake in comparison
with the non-treated B16-bearing mice (Figure 1). Conversely, sorafenib
treatment did not affect food intake in both the C26 and LLC models (Figure 1),
suggesting that feeding behaviour mainly depends on the tumour burden rather
than sorafenib administration.
Tumour growth led to a decrease in haematocrit in all the models tested, being
especially marked in the B16 (56%) and the LLC (56%) mice, where the tumour
mass was bigger (Figure 1). It is important to note that sorafenib administration
was effective in increasing the haematocrit (as compared with the non-treated
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animals) in both the B16 and LLC models, proportionally to the reduction of
tumour mass, thus linking directly the onset of anaemia with tumour burden.
(Figure S1)
The decreased body weight was associated with a concomitant loss of muscle
mass. As can be seen in Table 1, tumour growth promoted decreases in individual
muscle weights in the three different models tested. In the case of C26,
gastrocnemius (21%), tibialis (22%) and heart (13%) were decreased as a
consequence of tumour growth. In the other models gastrocnemius and tibialis
Figure 1. Body weight, food intake and haematocrit content in sorafenib-treated tumour-bearing mice. Results are mean¡ S.E.M. for 6–8 animals.
Food intake represents the total ingestion (g) during the period of the experiment prior to sacrifice, which took place 14 days after tumour inoculation. Final
body weight excludes the tumour weight. The haematocrit is expressed in percentage. C: animals without tumour (n56); C26: C26 adenocarcinoma-bearing
mice (n58); C26 Sor: C26 adenocarcinoma-bearing mice treated with sorafenib (n58); B16: B16 melanoma-bearing mice (n58); B16 Sor: B16 melanoma-
bearing mice treated with sorafenib (n58); LLC: Lewis lung carcinoma-bearing mice (n58); LLC Sor: Lewis lung carcinoma-bearing mice treated with
sorafenib (n58). Values that are significantly different of the results by one-way analysis of variance (ANOVA), statistically significant differences by post hoc
Duncan test. Different letters in superscript indicate significant differences between groups.
doi:10.1371/journal.pone.0113931.g001
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were significantly reduced (18% GSN, 14% tibialis for B16; 29% GSN, 27% tibialis
for LLC). No effects of tumour growth were observed in the heart neither in the
B16 nor in the LLC tumour models. Sorafenib treatment had significant effects in
the rescue of both gastrocnemius and tibialis mass in the C26 animal model (
Table 1), despite the ineffectiveness against tumour growth. Similarly, the
treatment caused a recovery of the gastrocnemius muscle in the LLC model;
however it did not have any statistical effects on the tibialis muscle. Concerning
the muscle, in contrast with the prevention of body weight loss, no statistically
significant effects were observed in the B16 animals after sorafenib administration.
As can be seen in Table 2, in addition to skeletal muscle, tumour growth
determined a very important decrease in white adipose tissue mass. Indeed,
Figure 2. Tumour weights in sorafenib-treated mice. Results are mean¡ S.E.M. for 6–8 animals. Tumour
weights are expressed in g. In the LLC model metastatic content is represented as % of invaded lung surface.
C26: C26 adenocarcinoma-bearing mice (n58); C26 Sor: C26 adenocarcinoma-bearing mice treated with
sorafenib (n58); B16: B16 melanoma-bearing mice (n58); B16 Sor: B16 melanoma-bearing mice treated with
sorafenib (n58); LLC: Lewis lung carcinoma-bearing mice (n58); LLC Sor: Lewis lung carcinoma-bearing
mice treated with sorafenib (n58). Values that are significantly different of the results by one-way analysis of
variance (ANOVA), * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0113931.g002
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cachexia is linked with muscle wasting and adipose tissue loss [6, 31]. A recent
report suggests that muscle wasting is linked to the loss of adipose tissue; if fat
mobilization is prevented, muscle wasting does not take place, at least in
experimental animals [32]. The largest reduction is observed in the LLC-bearing
animals, with losses over 90% of total tissue. Sorafenib treatment induced a rescue
of adipose tissues in all the cachexia models tested, the amelioration being
especially marked in the case of B16 where almost total recovery is accomplished,
explaining partially the above reported discrepancy between body and muscle
wasting. This observation is particularly interesting since sorafenib, despite
inducing an almost complete adipose tissue recovery, exerted only negligible
effects on skeletal muscle. From this point of view, the present data do not
support the conclusions of Das et al. [32], since the complete recovery of adipose
tissue is not sufficient to promote muscle sparing.
Table 1. Muscle and heart weights in sorafenib-treated tumour-bearing mice.
Tumour model Muscle Experimental groups
C T T Sor ANOVA
C26 GSN 562¡9 c 445¡17 a 500¡15 b 0,000
Tibialis 192¡3 c 149¡7 a 168¡6 b 0,000
Heart 502¡15 b 439¡14 a 477¡16 ab 0,025
B16 GSN 634¡21 b 522¡24 a 565¡17 a 0,010
Tibialis 193¡8 b 166¡8 a 178¡8 ab 0,073
Heart 586¡31 514¡21 512¡25 ns
LLC GSN 551¡16 c 390¡18 a 468¡7 b 0,000
Tibialis 189¡9 b 138¡6 a 157¡11 a 0,005
Heart 550¡35 536¡27 551¡11 ns
Results are mean ¡ S.E.M. Muscle weights are expressed as mg/100 g of initial body weight. GSN: gastrocnemius muscle. C: animals without tumour
(n56); T: tumour-bearing animals (n58); T Sor: tumour-bearing animals treated with sorafenib (n58). Values significantly different of the results by one-way
analysis of variance (ANOVA), statistically significant differences by post hoc Duncan test. Different letters in superscript indicate significant differences
between groups.
doi:10.1371/journal.pone.0113931.t001
Table 2. White adipose weights in sorafenib-treated tumour-bearing mice.
Tumour model Adipose Experimental groups
C T T Sor ANOVA
C26 WATd 684¡71 b 29¡18 a 285¡56 b 0,000
WATe 2043¡172 b 460¡129 a 1410¡149 b 0,000
B16 WATd 374¡38 b 140¡29 a 290¡13 b 0,000
WATe 1554¡103 b 811¡73 a 1425¡24 b 0,000
LLC WATd 315¡47 b 16¡3 a 35¡4 a 0,000
WATe 1298¡9 b 171¡36 a 259¡14 a 0,000
Results are mean¡ S.E.M. Adipose weights are expressed as mg/100 g of initial body weight. WATd: White adipose tissue dorsal; WATe: White adipose
tissue epididymal. C: animals without tumour (n56); T: tumour-bearing animals (n58); T Sor: tumour-bearing animals treated with sorafenib (n58). Values
significantly different of the results by one-way analysis of variance (ANOVA), statistically significant differences by post hoc Duncan test. Different letters in
superscript indicate significant differences between groups.
doi:10.1371/journal.pone.0113931.t002
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Taking into consideration the fact that the rescue of muscle mass does not
necessarily mean a concomitant recovery of muscle function [33], we decided to
measure total physical activity as a surrogate for muscle function and behavioural
adaptation. Figure 3 depicts total activity, maximum speed and distance travelled
by the animals. As it can be seen, tumour burden resulted in a considerably
decrease in all these parameters. The most affected animals were the LLC mice,
where total activity (78%), maximum velocity (65%), and distance (82%) were
reduced. Sorafenib treatment improved total physical activity in the three models
studied. It is interesting to remark that the largest improvement was observed in
Figure 3. Kinetic parameters in sorafenib-treated tumour-bearing mice. Results are mean¡ S.E.M. for 6–8 animals. Physical activity is expressed in
number of movements. Maximum velocity is expressed in cm/s. Travelled distance is expressed in cm. C: animals without tumour (n56); C26: C26
adenocarcinoma-bearing mice (n58); C26 Sor: C26 adenocarcinoma-bearing mice treated with sorafenib (n58); B16: B16 melanoma-bearing mice (n58);
B16 Sor: B16 melanoma-bearing mice treated with sorafenib (n58); LLC: Lewis lung carcinoma-bearing mice (n58); LLC Sor: Lewis lung carcinoma-
bearing mice treated with sorafenib (n58). Values that are significantly different of the results by one-way analysis of variance (ANOVA), statistically
significant differences by post hoc Duncan test. Different letters in superscript indicate significant differences between groups.
doi:10.1371/journal.pone.0113931.g003
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Figure 4. Circulating IL-6 levels in sorafenib-treated tumour-bearing mice. Results are mean¡ S.E.M. for 6–8 animals. IL-6 levels are expressed in pg/
mL. C: animals without tumour (n56); C26: C26 adenocarcinoma-bearing mice (n58); C26 Sor: C26 adenocarcinoma-bearing mice treated with sorafenib
(n58); B16: B16 melanoma-bearing mice (n58); B16 Sor: B16 melanoma-bearing mice treated with sorafenib (n58); LLC: Lewis lung carcinoma-bearing
mice (n58); LLC Sor: Lewis lung carcinoma-bearing mice treated with sorafenib (n58). Values that are significantly different of the results by one-way
analysis of variance (ANOVA), statistically significant differences by post hoc Duncan test. Different letters in superscript indicate significant differences
between groups.
doi:10.1371/journal.pone.0113931.g004
Figure 5. Correlation between the tumour reduction induced by sorafenib and the circulating IL-6 levels. N520 (B16, n56; C26, n57; LLC, n57).
Pearson Correlation. ** Correlation is statistically significant at 0,01 level (bilateral).
doi:10.1371/journal.pone.0113931.g005
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the B16 model, precisely where sorafenib treatment was not able to fully revert
muscle wasting. Therefore, some other factors must be taken into consideration
for explaining the improvement in total activity, including the reduction of the
tumour mass. It is possible to speculate that animal activity does not rely on the
muscle mass alone, rather depending also on the energy availability (fat included)
and the presence of anaemia, a clear limiting factor for physical activity. Sorafenib
treatment also improved maximum velocity in the LLC model (Figure 3).
Concerning the distance travelled, the treatment improved this parameter in all
the models tested, independently from the distinct effect exerted on tumour
burden.
In order to explain the mechanisms accounting for the tumour-independent
sorafenib effects, we determined the circulating concentrations of IL-6, a cytokine
that has been reported to be affected by sorafenib, which reduces its release [26].
Interestingly, in both C26 and LLC-bearing mice, where the levels of IL-6 are high
as a consequence of tumour growth, sorafenib did not lower the cytokine
concentration, suggesting that sorafenib effects do not directly rely on IL-6
Figure 6. Intracellular signals of skeletal muscle (gastrocnemius) in sorafenib-treated mice bearing the C26 adenocarcinoma. Results are mean¡
S.E.M. C: animals without tumour; C26: C26 carcinoma-bearing mice; C26+sor: C26 adenocarcinoma-bearing mice treated with sorafenib. Values that are
significantly different of the results by one-way analysis of variance (ANOVA), statistically significant difference by post hoc Duncan test. Different letters in
superscript indicate significant differences between groups.
doi:10.1371/journal.pone.0113931.g006
Cancer Cachexia in Sorafenib-Treated Tumour-Bearing Mice
PLOS ONE | DOI:10.1371/journal.pone.0113931 December 1, 2014 11 / 16
inhibition (Figure 4). It has to be pointed out that muscle IL-6 concentration
could be altered by the treatment; differences in receptor content are another
possibility. Unfortunately, we have not assessed these possibilities. However, it is
interesting to point out that the anti-tumour effect of sorafenib was stronger when
IL-6 circulating levels were low, as in the B16-bearing mice, existing a good
correlation between the degree of tumour reduction and the concentration of IL-6
(Figure 5) in the different models tested. It seems, therefore, that sorafenib anti-
tumour action is more effective in low IL-6 conditions.
In order to further investigate the mechanisms by which sorafenib exerts its
effects, we determined the intramuscular concentration and activation state of
several proteins that might be involved in the sorafenib action. As far as we are
concerned, there are no reports suggesting a direct kinase-inhibiting action of
sorafenib in the skeletal muscle. For this part of the study we only used the C26
model, since in this setting, despite the absence of drug effects on tumour burden,
sorafenib improved both muscle weight and activity parameters. The results
depicted in Figure 6 show that tumour growth resulted in a significant nuclear
accumulation of Pax7, a protein involved in muscle regeneration [34, 35],
concomitant with the hyperactivation of the kinases ERK and STAT3, that were
reported to be critical for the onset of muscle wasting in C26 mice [34–36].
Surprisingly, sorafenib significantly decreased the concentration of Pax7 and the
activation of the above-mentioned kinases. Consistent with previous observations
showing that ERK inhibition prevented the activation of the ubiquitin ligase
Figure 7. Possible intracellular pathways linked with sorafenib action in skeletal muscle.
doi:10.1371/journal.pone.0113931.g007
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atrogin-1 [34], sorafenib administration was able to reduce the atrogin-1 protein
accumulation in C26 mice (Figure 6), likely limiting the catabolic stimulus. Such
effect seems independent from the activation of the transcription factor FoxO3a,
as the nuclear (i.e. active) levels of the protein did not change in C26 mice and
slightly decreased in sorafenib-treated C26 animals, confirming that the Akt/FoxO
pathway is not involved in the onset of muscle wasting [37], at least in this
experimental setting. These results suggest that sorafenib exerts its anti-cachectic
action directly on the muscle by inhibiting either the STAT3 or ERK pathways,
independently from IL-6 serum levels (Figure 7). Recent observations point out
the suppressive role played by STAT3 in satellite cell-mediated muscle
regeneration [38, 39] and, consistently, the anti-cachectic action exerted by
sorafenib is stronger in the experimental model of cachexia where muscle
regeneration is more affected.
In conclusion, the results presented here reinforce the idea that sorafenib is an
efficient drug for the treatment of tumours in addition to being a candidate for
anti-cachectic therapy. This is based on the fact that any reduction in tumour
mass results in a reduction in cachexia and also in the fact that, even without
affecting the tumour, it does behave as an anti-cachectic molecule, as observed
in the C26 tumour model. Yet, previous studies actually conclude that
sorafenib per se induces wasting [23, 40]; therefore further studies in this field
are needed and might lead to a new promising drug combination for the
treatment of cachexia.
Supporting Information
Figure S1. Correlation between tumour mass (expressed as % of the mean) and
haematocrit in the three tumour models. Pearson analysis shows a significant
correlation of tumour versus haematocrit in B16 (Pearson r50.789; p50.004,
n512) and a tendency in LLC (Pearson r50.526; p50.065, n513). No correlation
is present in C26 (Pearson r50.120; p50.6, n514).
doi:10.1371/journal.pone.0113931.s001 (TIF)
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